Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Acquired resistance to erlotinib and cisplatin is a major challenge in non-small cell lung cancer (NSCLC) treatment.
• MicroRNAs (miRNAs) play a crucial role in regulating epithelial-to-mesenchymal transition (EMT), a process linked to drug resistance in NSCLC.

Purpose of the Study:

• To investigate the effect of garcinol, a dietary factor from *Garcinia indica*, on drug-resistant NSCLC cells.
• To elucidate the role of miRNAs and EMT in garcinol's sensitization of NSCLC cells to standard therapies.

Main Methods:

• Induction of mesenchymal phenotype and drug resistance in A549 cells using transforming growth factor beta 1 (TGF-β1) to create A549M cells.
• Treatment of A549M and H1299 NSCLC cells with garcinol and assessment of sensitization to erlotinib and cisplatin.
• Analysis of EMT markers (E-cadherin, vimentin, ZEB1) and EMT-regulating miRNAs (miR-200b, miR-205, miR-218, let-7c) after garcinol treatment.
• Inhibition of miRNA activity using anti-miRNA transfections to evaluate garcinol's mechanism of action.

Main Results:

• Garcinol significantly sensitized mesenchymal, drug-resistant NSCLC cells (A549M) to erlotinib and cisplatin, reducing their IC50 values.
• Garcinol enhanced erlotinib-induced apoptosis in A549M and H1299 cells.
• Garcinol upregulated key EMT-regulating miRNAs, including miR-200b, miR-205, miR-218, and let-7c.
• Anti-miRNA transfection studies confirmed that miRNAs, particularly miR-200c and let-7c, mediate garcinol's reversal of EMT and sensitization of NSCLC cells.

Conclusions:

• Garcinol effectively reverses EMT and overcomes acquired drug resistance in NSCLC.
• miRNAs, specifically miR-200c and let-7c, are critical mediators of garcinol's therapeutic effects in NSCLC.
• Garcinol holds potential as a sensitizing agent to improve the efficacy of standard NSCLC therapies.